New blood test distinguishes between IBD, IBS

Analyte Health announced that it now offers a new test to help health care providers determine if a patient has inflammatory bowel disease or irritable bowel syndrome, according to a press release.

The test, IsolateIBS-IBD, — developed in a partnership with IQuity Inc. — uses RNA expression analysis to determine the correct diagnosis with 90% accuracy, according to the release.

“IsolateIBS-IBD offers an accurate new tool for patients and providers to identify irritable bowel syndrome or inflammatory bowel disease at the earliest onset of symptoms, and to distinguish among IBS, Crohn’s and ulcerative colitis,” Chase Spurlock, PhD, CEO of IQuity Inc. said in the press release. “The earlier a patient receives an accurate diagnosis, the faster an appropriate treatment can be developed with their provider.”

The test uses a blood draw that patients can perform at home. Clinicians can use the test as an alternative to more expensive existing tests that rely on a combination of blood, stool and tissue samples to determine a diagnosis, according to the press release.

Approximately 30 million people in the United States have IBS, but less than half of them have received proper diagnosis. More than 1.6 million people in the U.S. have IBD, according to the press release.

“Given the prevalence of IBS and IBD in the US population, and the historical challenges of acquiring a timely and accurate diagnosis, we are thrilled to be able to use this innovative test to help providers and patients achieve clarity around their medical conditions,” Frank Cockerill, MD, chief medical officer of Analyte Health said in the press release.

Disclosures: Spurlock is employed by IQuity, Inc. Cockerill is employed by Analyte Health.

Analyte Health announced that it now offers a new test to help health care providers determine if a patient has inflammatory bowel disease or irritable bowel syndrome, according to a press release.

The test, IsolateIBS-IBD, — developed in a partnership with IQuity Inc. — uses RNA expression analysis to determine the correct diagnosis with 90% accuracy, according to the release.

“IsolateIBS-IBD offers an accurate new tool for patients and providers to identify irritable bowel syndrome or inflammatory bowel disease at the earliest onset of symptoms, and to distinguish among IBS, Crohn’s and ulcerative colitis,” Chase Spurlock, PhD, CEO of IQuity Inc. said in the press release. “The earlier a patient receives an accurate diagnosis, the faster an appropriate treatment can be developed with their provider.”

The test uses a blood draw that patients can perform at home. Clinicians can use the test as an alternative to more expensive existing tests that rely on a combination of blood, stool and tissue samples to determine a diagnosis, according to the press release.

Approximately 30 million people in the United States have IBS, but less than half of them have received proper diagnosis. More than 1.6 million people in the U.S. have IBD, according to the press release.

“Given the prevalence of IBS and IBD in the US population, and the historical challenges of acquiring a timely and accurate diagnosis, we are thrilled to be able to use this innovative test to help providers and patients achieve clarity around their medical conditions,” Frank Cockerill, MD, chief medical officer of Analyte Health said in the press release.

Disclosures: Spurlock is employed by IQuity, Inc. Cockerill is employed by Analyte Health.